ABSTRACT OBJECTIVES This study aimed to investigate sympathetic nerve (SN) ultrastructural changes and hemodynamic and pulmonary artery (PA) pathological improvements by pulmonary arterial denervation (PADN) in animals with pulmonary arterial hypertension (PAH), as well as the underlying mechanisms.
The innervation of the PA is predominantly sympathetic (8) , and increased sympathetic nerve (SN) activity and circulating catecholamines (9) (10) (11) have been demonstrated in patients with PAH, suggesting that SN overactivation plays a critical role in PAH. Trials targeting sympathetic activation have been undertaken; however, in contrast to left heart failure, nonselective betablockers reduce exercise capacity and worsen hemodynamics in patients with PAH (1, 12, 13) . This outcome may be explained by the complex innervation of the PA and the variety of neurotransmitters and cotransmitters delivered to the pulmonary vasculature (8, 14, 15) . Surgical denervation of the pulmonary artery abolishes the increase in pulmonary arterial pressure (PAP) induced by PA extension in experimental models (16). This effect has also been demonstrated using percutaneous pulmonary artery denervation (PADN) to abolish balloon inflation-induced increases in PA pressure in a dog model (17) and in patients with PAH (18) . However, little published data demonstrates the pathological improvements and the associated mechanisms of PADN (19) . Accordingly, the current study aimed to 
HEMODYNAMIC

MEASUREMENTS.
The hemodynamic measurements have been described previously (17, 18) . Briefly, at 14 weeks, a 7-F sheath was inserted into the femoral vein, and a Swan-Ganz catheter (Edwards Lifesciences, Irvine, California) was positioned at the distal PA.
with hematoxylin. The tissues were examined using a Leica TSL laser confocal microscope (Leica Microsystems Inc., Bannockburn, Illinois), and the distance from the nerve endings to the PA vessel walls was measured.
3-DIMENSIONAL RECONSTRUCTION OF PA AND SYMPATHETIC NERVES. All of the images of SN staining with PA vessel walls were converted into grayscale from RGB, repeat coded with Grim software (Vision Co., Nanjing, China), and then imported into a blender to build the frame of the 3-dimensional PA.
Then, all of the nerve endings were completely combined with the 3-dimensional PA model. Zhou et al.
from each dog were analyzed under an Olympus-BHS Values are mean AE SD. *p < 0.001, compared with all groups; †p < 0.01, compared with prior to PADN group and normal animals; ‡p < 0.001, compared with all subgroups in after PADN group; §p < 0.001, compared with 1, 2, and 3 months groups; kp < 0.01, compared with mPAP #25 mm Hg, 2 months, and 3 months groups; ¶p < 0.05, compared with the 3 months group.
mPAP mean pulmonary arterial pressure; PADN pulmonary artery denervation; SNCV sympathetic nerve conduction velocity.
FIGURE 3 Ultrastructural Change, SNCV, Axon Diameter, and Myelin Thickness
Before PADN, the myelin appeared smooth, and the mean SNCV was 48.1 m/s (A to F), with a mean myelin thickness of 1.62 mm (G) and an axon diameter of 5.98 mm (H). After the PADN procedure, the myelin thickness gradually decreased and was almost demyelinated by 3 months (SN).
This result is consistent with the reduction of SNCV and axon loss. Abbreviations as in Figure 1 .
PADN Improving PA Remodeling all of the continuous variables was performed using the Kolmogorov-Smirnov and Shapiro-Wilk tests.
The differences in the continuous variables between the 2 treatments were analyzed using a paired t test or the Mann-Whitney U test when appropriate. Post-hoc analysis using Bonferroni's method was used to compare the 3 groups. The categorical variables were compared using the Fisher exact test. Statistical significance was defined as a 2-sided p value <0.05. Finally, the sham group contained 7 dogs, and the PADN group contained 9 animals. PADN PROCEDURE. PADN was performed at 3 sites (Figures 2A to 2C) . The median procedural time was 
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Zhou et al. Figure 3A ).
After the PADN procedure, the SNCV decreased very rapidly over time ( Figures 3B to 3F ).
ELECTRON MICROSCOPIC ASSESSMENT OF SN.
Most nerve endings in animals with mPAP >25 mm Hg had smooth and relatively thick myelin (Figures 3, left panels [SN] ), with a mean myelin thickness of 1.62 mm and a mean axon diameter of 5.98 mm (Figures 3G and 3H) , significantly higher than those (5.27 and 1.13 xm, respectively) in animals with mPAP #25 mm Hg ( Table 1) . After the PADN procedure, the myelin sheath became noticeably thinner and the vacuoles degenerated over time (Table 1) , with axon diameters significantly decreased to 3.53 Values are mean AE SD. *p 0.005 compared with the PADN and sham groups; †p < 0.001 compared with the PADN and sham groups; ‡p 0.008 compared with the PADN and sham groups; §p < 0.05 compared with value measured at week 14; kp < 0.001 compared with the sham group; ¶p < 0.01 compared with value at week 14; #p 0.005 compared with the sham group. mPAP mean pulmonary arterial pressure; MWT medial wall thickness; PA pulmonary artery; PVR pulmonary vessel resistance; RAP right atrial pressure; RVSP right ventricular systolic pressure; sPAP systolic pulmonary arterial pressure. The proliferation of PA smooth muscle cells, leading to the increased muscularization of tiny arterioles and reduced vascular lumen, is the hallmark of PAH (1) (2) (3) 15) . The reverse of this pathological process is the primary endpoint of testing for potential therapies in animal models (25, 26) . Previous data revealed that SN overactivation was strongly correlated with the severity and prognosis of PAH (9) (10) (11) and that nebi- Molecular studies (7, 26, 27) have shown that growth factors synthesized by many different cell types, coupled with an increase of endothelial nitric oxide synthase (causing endothelial dysfunction and apoptosis resistance) (28) (29) (30) , endothelin-1 (31), and monocyte chemoattractant protein-1 (27) , play an important role in the pulmonary vascular remodeling process responsible for the progression of PAH. Our finding that PADN attenuates PA remodeling by inhibiting abnormal cell growth is consistent with a previous study using nebivolol (26) ; however, the latter study did not find the reduction of fibroblast growth factor-2 after a high dose of nebivolol, indi- In contrast to studies using small animal models, the success rate of establishing the PADN model in dogs was relatively reduced (w70%). However, in the present study, dogs with mPAP #25 mm Hg were excluded from the study for PA remodeling. Next, our study did not provide insights into the effect of PADN on different transmitters and the protein phosphorylation of signal molecules. However, our preliminary data unmasked the mechanisms of PA remodeling improvement by PADN. Third, the fraction of inspired oxygen was not collected in this study. Finally, the DHMCT-induced PAH model did not represent human PAH in terms of pathological changes (29) . Further work will be required to test the efficacy of PADN in other PAH models.
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CONCLUSIONS
Our results report that PADN induces SN injury and improves hemodynamics and PA remodeling, and provide the associated molecular mechanisms.
Further studies are required to fine-tune the methodology of the ablation and to elucidate the long-term efficacy in different PAH models. 
